OraSure Technologies (OSUR) Resumen de Acciones
OraSure Technologies, Inc., junto con sus filiales, desarrolla, fabrica, comercializa, vende y distribuye productos de diagnóstico y dispositivos de recogida de muestras en Estados Unidos, Europa, África e internacionalmente. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 1/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Análisis de riesgos
No se han detectado riesgos en OSUR a partir de nuestros controles de riesgos.
OSUR Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de OraSure Technologies, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$3.61 |
| Máximo en las últimas 52 semanas | US$3.82 |
| Mínimo de 52 semanas | US$2.08 |
| Beta | 0.89 |
| Cambio en 1 mes | 15.71% |
| Variación en 3 meses | 31.27% |
| Cambio de 1 año | 43.25% |
| Variación en 3 años | -26.02% |
| Variación en 5 años | -62.43% |
| Variación desde la OPV | -34.36% |
Noticias y actualizaciones recientes
Actualización de narrativa • May 02
OSUR: Altai Cooperation And Board Changes Will Support Future Upside
Analysts have nudged their price target on OraSure Technologies slightly higher to $4.00, reflecting updated assumptions around the discount rate, modest revenue growth expectations, profit margin adjustments, and a revised future P/E multiple. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management that includes appointing John D.
Actualización de narrativa • Apr 18
OSUR: Altai Cooperation Agreement Will Drive Future Upside Potential
Analysts have adjusted their price target on OraSure Technologies to reflect a fair value of $5.00, citing updated assumptions for the discount rate, profit margin, and future P/E ratio as the key drivers of this change. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management, adding John D.Recent updates
Actualización de narrativa • May 02
OSUR: Altai Cooperation And Board Changes Will Support Future Upside
Analysts have nudged their price target on OraSure Technologies slightly higher to $4.00, reflecting updated assumptions around the discount rate, modest revenue growth expectations, profit margin adjustments, and a revised future P/E multiple. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management that includes appointing John D.Actualización de narrativa • Apr 18
OSUR: Altai Cooperation Agreement Will Drive Future Upside Potential
Analysts have adjusted their price target on OraSure Technologies to reflect a fair value of $5.00, citing updated assumptions for the discount rate, profit margin, and future P/E ratio as the key drivers of this change. What's in the News On April 17, 2026, OraSure Technologies entered into a Cooperation Agreement with Altai Capital Management, adding John D.Actualización de narrativa • Apr 01
OSUR: Activist Campaign And Governance Changes Will Support Future Upside
Analysts have made a modest adjustment to their price target for OraSure Technologies to $4.00, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E multiple. What's in the News Altai Capital Management has escalated its campaign, calling for a broad review of options including a potential sale of OraSure Technologies, criticizing executive pay and board oversight, and urging shareholders to support its director nominees Rishi Bajaj and John Bertrand at the 2026 annual meeting (Investor Activism, March 18, 2026).Actualización de narrativa • Mar 18
OSUR: Activist Board Push And Buybacks Will Support Future Upside
Analysts have lifted their price target on OraSure Technologies to $4.00 from $3.00, citing updated expectations regarding revenue growth, profit margins, and a modestly higher future P/E multiple. What's in the News Altai Capital Management sent a letter to OraSure's board on March 17, 2026, outlining a five-pillar case for change, citing share price underperformance, board ownership levels, CEO pay structure, a call for a strategic review, and support for its nominees, Rishi Bajaj and John Bertrand, to join the board (Investor Activism) Altai Capital formally nominated Bajaj and Bertrand for election to the board at the 2026 Annual Meeting and submitted a proposal to declassify the board so all directors stand for annual elections (Investor Activism) OraSure issued first quarter 2026 guidance, projecting total revenues of US$26 million to US$29 million, with only a negligible contribution from COVID 19 testing (Corporate Guidance) The company reported completing a share repurchase of 5,245,180 shares, or 7.12% of its stock, for US$14.89 million under a buyback program announced on March 24, 2025, including 1,900,000 shares bought for US$5 million between October 1 and December 31, 2025 (Buyback Tranche Update) OraQuick HIV Self Test received a Health Canada license as the first oral HIV self test in Canada, offering 20 minute results from an oral swab and distribution through St. Michael's Hospital to support access across healthcare and community settings (Product Related Announcement) Valuation Changes Fair Value: The analyst fair value estimate has risen from $3.00 to $4.00 per share, which represents a material upward revision to the target level.Actualización de narrativa • Mar 04
OSUR: New STI Self Testing Submissions Will Drive Future Upside
Analysts have raised their price target on OraSure Technologies from $4.50 to $5.00, citing updated assumptions around revenue growth, profit margin and future P/E that they state better reflect the company’s current outlook. What's in the News OraSure completed a share repurchase tranche between October 1, 2025 and December 31, 2025, buying 1,900,000 shares, or 2.63% of shares, for US$5 million.Actualización de narrativa • Feb 18
OSUR: New STI Self Testing Submissions Will Support Future Shareholder Upside
Narrative Update on OraSure Technologies Analysts have kept their OraSure Technologies fair value estimate steady at $4.50, with only marginal tweaks to inputs like the discount rate, long term revenue growth, profit margin, and future P/E assumptions driving this maintained price target. What's in the News OraQuick HIV Self-Test received a Health Canada license, becoming Canada's first oral HIV self test and offering results in about 20 minutes from an oral swab for HIV 1 and HIV 2 antibodies.Actualización de narrativa • Feb 04
OSUR: New STI Testing Submissions Will Drive Future Shareholder Value
Analysts have modestly revised their price target for OraSure Technologies to US$4.50, reflecting slightly adjusted assumptions on discount rate, revenue growth, profit margin, and future P/E. These changes leave their overall view of the company’s fair value essentially unchanged.Actualización de narrativa • Jan 21
OSUR: At-Home STI Testing Pipeline Will Drive Future Upside
Analysts have maintained their price target on OraSure Technologies at US$3.00. This reflects updated views on factors such as discount rate, revenue growth assumptions, profit margins, and future P/E expectations, while keeping the headline valuation level unchanged.Actualización de narrativa • Jan 07
OSUR: At-Home STI Testing And Activist Push Will Drive Future Upside
Analysts have kept their fair value estimate for OraSure Technologies steady at US$3.00 per share, citing largely unchanged assumptions around the company’s discount rate, revenue growth outlook, profit margin profile, and future P/E multiple. What's in the News OraSure submitted two applications to the U.S. FDA at the end of 2025 for clearance of a rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae and for its Colli-Pee at-home urine collection device for sexually transmitted infections, both aimed at over-the-counter and at-home use (Key Developments).Actualización de narrativa • Dec 23
OSUR: Activist Board Challenge Will Drive Future Shareholder Value Upside
Analysts have reduced their price target on OraSure Technologies from 5.00 dollars to 3.00 dollars per share, citing a higher required return on equity and lower expected future valuation multiples, despite improving revenue growth assumptions and largely stable profit margins. What's in the News Altai Capital Management notified OraSure Technologies Board on December 17, 2025 of its intention to nominate two directors at the 2026 annual meeting, citing share price underperformance and capital allocation concerns (Key Developments).Actualización de narrativa • Dec 09
OSUR: Ongoing Share Repurchases Will Drive Future Shareholder Value
Analysts have raised their price target on OraSure Technologies from 4.50 dollars to 4.75 dollars, citing slightly lower discount rate assumptions and a modestly higher long term valuation multiple, despite a small reduction in projected profit margins. What's in the News Completed a share repurchase of 3,345,180 shares, representing 4.49% of outstanding shares, for a total of $9.89 million under the buyback program announced on March 24, 2025 (Key Developments) From July 1, 2025 to September 30, 2025, repurchased 1,524,424 shares, or 2.07% of outstanding shares, for $4.9 million as the latest tranche of the ongoing buyback (Key Developments) Issued fourth quarter 2025 earnings guidance, projecting total revenues of $25 million to $28 million (Key Developments) Q4 2025 outlook includes less than $100,000 in COVID-19 testing revenue, underscoring the company’s pivot away from pandemic-driven sales (Key Developments) Valuation Changes Fair Value Estimate remains unchanged at 4.50 dollars per share, indicating no revision to the intrinsic value assessment.Actualización de narrativa • Nov 25
OSUR: Share Buybacks And Board Actions Will Drive Shareholder Value
Narrative Update: Analyst Price Target Adjustment for OraSure Technologies Analysts have reduced OraSure Technologies’ price target from $4.75 to $4.50, citing updated assumptions in growth and profitability metrics. What's in the News OraSure Technologies repurchased 1,524,424 shares for $4.9 million during Q3 2025, completing a total buyback of 3,345,180 shares under the repurchase plan announced in March 2025 (Key Developments).Artículo de análisis • Nov 14
Revenues Working Against OraSure Technologies, Inc.'s (NASDAQ:OSUR) Share Price Following 25% Dive
OraSure Technologies, Inc. ( NASDAQ:OSUR ) shares have had a horrible month, losing 25% after a relatively good period...Actualización de narrativa • Nov 06
OSUR: Activist Pressure Will Drive Shareholder Value Amid Board Challenge
Analysts have revised their price target for OraSure Technologies from $6.00 to $4.75, citing updated projections for revenue growth and broader shifts in valuation estimates. What's in the News Healthcare entrepreneur Ron Zwanziger warned OraSure that he may pursue an adversarial strategy if the company continues to resist his acquisition bid, following OraSure's rejection of his all-cash offer earlier this summer (Reuters).Artículo de análisis • Aug 08
OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results
There's been a notable change in appetite for OraSure Technologies, Inc. ( NASDAQ:OSUR ) shares in the week since its...Seeking Alpha • Jul 28
OraSure Technologies: An Asymmetric Bet
Summary OraSure trades near cash value with minimal debt, reflecting excessive market pessimism and creating an asymmetric risk-reward opportunity. The company's future hinges on Sherlock's at-home STD test kit, with a high probability of FDA approval and strong market potential. Management is actively streamlining operations, divesting non-core assets, and positioning OraSure as an attractive acquisition target. Downside risk is limited by a strong balance sheet and buyback program, while acquisition or Sherlock's success could drive significant upside. Read the full article on Seeking AlphaArtículo de análisis • May 08
Shareholders Will Probably Hold Off On Increasing OraSure Technologies, Inc.'s (NASDAQ:OSUR) CEO Compensation For The Time Being
Key Insights OraSure Technologies will host its Annual General Meeting on 14th of May Total pay for CEO Carrie Eglinton...Artículo de análisis • Feb 27
Investors Don't See Light At End Of OraSure Technologies, Inc.'s (NASDAQ:OSUR) Tunnel And Push Stock Down 26%
OraSure Technologies, Inc. ( NASDAQ:OSUR ) shareholders won't be pleased to see that the share price has had a very...
Nueva narrativa • Feb 09
Launch Of OraQuick HCV Self-Test And Genomics Ventures Will Open Markets Amid Profitability Pressures
The international launch of the OraQuick HCV Self-test and upcoming blood proteomics launch offer significant revenue and growth opportunities.Seeking Alpha • Dec 11
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Summary OraSure Technologies is undervalued, trading below its net current asset value, offering a compelling risk-reward scenario with limited downside risk. The company has a robust balance sheet with no long-term debt and $280 million in cash, mitigating downside risks. Post-COVID margins are expected to improve, driving positive cash flow and substantial upside potential, with a projected 70%+ appreciation. Management is competent and aligned with shareholders, enhancing confidence in the company’s ability to capitalize on its undervaluation. Read the full article on Seeking AlphaArtículo de análisis • Nov 14
Some May Be Optimistic About OraSure Technologies' (NASDAQ:OSUR) Earnings
Shareholders appeared unconcerned with OraSure Technologies, Inc.'s ( NASDAQ:OSUR ) lackluster earnings report last...Artículo de análisis • Nov 08
Here's What Analysts Are Forecasting For OraSure Technologies, Inc. (NASDAQ:OSUR) After Its Third-Quarter Results
OraSure Technologies, Inc. ( NASDAQ:OSUR ) just released its third-quarter report and things are looking bullish...Seeking Alpha • Nov 04
OraSure: An NCAV Diamond In The COVID Rough
Summary OraSure Technologies Inc. is a health and wellness company specializing in "easy to use" diagnostic and specimen collection products. OraSure has a strong balance sheet and is trading below its net current asset value. At the same time, OraSure has a stable operational history with consistent normalized cash flow margins. OraSure has the potential to return to its (much higher) historical NCAV multiples, particularly when considering the new management teams' focus on operational efficiency through cost control. Read the full article on Seeking AlphaSeeking Alpha • Sep 10
OraSure Technologies: Nursing A COVID-19 Hangover
Summary Today, we revisit OraSure Technologies, Inc., a diagnostic firm that, like many in the industry, is going through a post-COVID hangover. The good news for the company is it is sitting on a huge cash balance and management is doing a good job of reducing operating expenses. An updated analysis around OraSure Technologies follows in the paragraphs below. Read the full article on Seeking AlphaArtículo de análisis • May 11
OraSure Technologies, Inc. (NASDAQ:OSUR) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a sad week for OraSure Technologies, Inc. ( NASDAQ:OSUR ), who've watched their investment drop 11% to...Artículo de análisis • Apr 17
Lacklustre Performance Is Driving OraSure Technologies, Inc.'s (NASDAQ:OSUR) Low P/S
With a price-to-sales (or "P/S") ratio of 1x OraSure Technologies, Inc. ( NASDAQ:OSUR ) may be sending very bullish...Artículo de análisis • Mar 01
Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
It's been a good week for OraSure Technologies, Inc. ( NASDAQ:OSUR ) shareholders, because the company has just...Artículo de análisis • Feb 29
Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Artículo de análisis • Dec 20
OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry
OraSure Technologies, Inc.'s ( NASDAQ:OSUR ) price-to-sales (or "P/S") ratio of 1.3x might make it look like a buy...Rentabilidad de los accionistas
| OSUR | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 20.3% | 4.4% | 1.0% |
| 1Y | 43.3% | -17.9% | 28.7% |
Rentabilidad vs. Industria: OSUR superó a la industria US Medical Equipment, que obtuvo un rendimiento del -17.9% el año pasado.
Rentabilidad vs. Mercado: OSUR superó al mercado US, que obtuvo un rendimiento del 28.7% el año pasado.
Volatilidad de los precios
| OSUR volatility | |
|---|---|
| OSUR Average Weekly Movement | 7.0% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: OSUR no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de OSUR (7%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1987 | 500 | Carrie Eglinton Manner | www.orasure.com |
OraSure Technologies, Inc., junto con sus filiales, desarrolla, fabrica, comercializa, vende y distribuye productos de diagnóstico y dispositivos de recogida de muestras en Estados Unidos, Europa, África e internacionalmente. Ofrece la prueba rápida del VIH OraQuick, el autotest del VIH OraQuick, el autotest del VIH OraQuick (internacional), la prueba rápida de anticuerpos y el autotest del VHC OraQuick, la prueba de diagnóstico rápido de sífilis Health Check, la prueba rápida de antígenos del ébola OraQuick, la prueba rápida InteliSwab COVID-19, la prueba rápida InteliSwab COVID-19 pro, la prueba rápida InteliSwab COVID-19 rx, la prueba SickleSCAN y el dispositivo de recogida de líquido oral OraSure para anticuerpos del VIH-1; sistemas de análisis de drogas Intercept; pruebas de inmunoensayo y reactivos; y Q.E.D. prueba de alcohol en saliva. La empresa también ofrece productos genómicos bajo las marcas Oragene y ORAcollect para la recogida de material genético de la saliva humana; dispositivos de recogida Colli-Pee para la recogida volumétrica de muestras de orina; y dispositivo de recogida de sangre proteica HEMAcollect.
Resumen de fundamentos de OraSure Technologies, Inc.
| Estadísticas fundamentales de OSUR | |
|---|---|
| Capitalización bursátil | US$226.51m |
| Beneficios(TTM) | -US$75.07m |
| Ingresos (TTM) | US$113.02m |
2.2x
Ratio precio-ventas (PS)-3.3x
Ratio precio-beneficio (PE)¿Está OSUR sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de OSUR | |
|---|---|
| Ingresos | US$113.02m |
| Coste de los ingresos | US$65.25m |
| Beneficio bruto | US$47.77m |
| Otros gastos | US$122.84m |
| Beneficios | -US$75.07m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.09 |
| Margen bruto | 42.27% |
| Margen de beneficio neto | -66.42% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado OSUR a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 11:32 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
OraSure Technologies, Inc. está cubierta por 15 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Charley Jones | Barrington Research Associates, Inc. |
| Karen Koski | BTIG |
| Mark Massaro | Canaccord Genuity |